Search Results

AviadoBio today announced that its Phase 1/2 ASPIRE-FTD clinical trial is now open and recruiting patients in the United States at The Ohio State University.

Zomedica Corp., a veterinary health company offering diagnostic and therapeutic products for equine and companion animals, completed the expansion of its global manufacturing and distribution facilities in Roswell, Georgia.

Inhalon Biopharma today announced a new agreement with the University of Georgia to license a panel of Human Metapneumovirus (hMPV) antibodies.

University Cancer & Blood Center, a leading oncology and hematology practice for Northeast Georgia, and University Health Alliance, a multi-disciplinary practice focusing on prevention and coordinated care, announce the opening of their High-Risk GI Clinic.

PAVmed Inc announced that Veris and The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, a National Cancer Institute-Designated Comprehensive Cancer Center, launched a pilot program and enrolled the first patients on the Veris Cancer Care Platform™ pursuant to a recently-executed memorandum of understanding.

ChromaCode, Inc. today announced a partnership with Department of Pathology, Medical College of Georgia , to test the analytical and clinical performance of ChromaCode’s HDPCR non-small cell lung cancer.

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a first-in-kind collaboration with Penn State University in the United States to create a shared research and education facility for the fast-developing microbiome sciences.

AN2 Therapeutics, Inc. today announced that it has received an exclusive license from the University of Georgia Research Foundation to advance the development of a boron-containing small molecule for Chagas disease.

PAVmed Inc. announced that Veris and The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, a National Cancer Institute-Designated Comprehensive Cancer Center, have executed a memorandum of understanding to implement a pilot program where cancer patients would be enrolled on the Veris Cancer Care Platform™.

Halberd Corporation’s Traumatic Brain Injury mitigating nasal spray testing protocols at Mississippi State University were approved by the Institutional Animal Care and Use Committee.